A CDR-based approach to generate covalent inhibitory antibody for human rhinovirus protease

Bioorg Med Chem. 2021 Jul 15:42:116219. doi: 10.1016/j.bmc.2021.116219. Epub 2021 May 19.

Abstract

Covalent target modulation with small molecules has been emerging as a promising strategy for drug discovery. However, covalent inhibitory antibody remains unexplored due to the lack of efficient strategies to engineer antibody with desired bioactivity. Herein, we developed an intracellular selection method to generate covalent inhibitory antibody against human rhinovirus 14 (HRV14) 3C protease through unnatural amino acid mutagenesis along the heavy chain complementarity-determining region 3 (CDR-H3). A library of antibody mutants was thus constructed and screened in vivo through co-expression with the target protease. Using this screening strategy, six covalent antibodies with proximity-enabled bioactivity were identified, which were shown to covalently target HRV14-3C protease with high inhibitory potency and exquisite selectivity. Compared to structure-based rational design, this library-based screening method provides a simple and efficient way for the discovery and engineering of covalent antibody for enzyme inhibition.

Keywords: CDR-H3; Covalent inhibition; Inhibitory antibody; Intracellular screening; Protease 3C; Proximity-enabled bioactivity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3C Viral Proteases / antagonists & inhibitors*
  • 3C Viral Proteases / metabolism
  • Antibodies / chemistry
  • Antibodies / pharmacology*
  • Complementarity Determining Regions / drug effects*
  • Cysteine Proteinase Inhibitors / chemistry
  • Cysteine Proteinase Inhibitors / pharmacology*
  • Dose-Response Relationship, Drug
  • Humans
  • Models, Molecular
  • Molecular Structure
  • Rhinovirus / enzymology*
  • Structure-Activity Relationship

Substances

  • Antibodies
  • Complementarity Determining Regions
  • Cysteine Proteinase Inhibitors
  • 3C Viral Proteases